Insys Therapeutics (INSY), the once high-flying drug maker that is among the companies blamed for fueling the U.S. opioid crisis, is in danger of going out of business.

A combination of financial losses and uncertainty about its cash position prompted its auditor to determine there is “substantial doubt” whether the company can continue “as a going concern,” according to documents filed with the Securities and Exchange Commission. The drug maker added that it is trying to raise funds, but conceded there are “no assurances” (see page 43).

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Excellent closing line – “The current Insys management has otherwise kept busy trying to develop cannabinoid products.” As I was reading, I wondered ‘what they were smoking’ to engage in such activities.

Your daily dose of news in health and medicine

Privacy Policy